Pfizer Inc. (PFE) — closed signal from March 7, 2026
Partial Published before the outcome was known, scored automatically when the window closed on June 5, 2026.
Predicted vs. what happened
What happened
Reached 79% of the predicted growth at its peak, without hitting the target.
The thesis — published March 7, 2026
Pfizer is presented as a steady, lower-risk healthcare pick rather than a fast-growing stock. Approval in China for its obesity drug gives a new growth story beyond older products, and the share price is settling after a long weak period. Expect moderate upside and uncertain vaccine and regulatory news, so take a cautious stance.
Primary drivers
- China approval gives a new growth story for the obesity drug
- Healthcare focus tends to hold up better in unstable markets
- Stock has begun to steady, so buy in small increments
- Big company size makes big losses less likely than small biotechs
How it played out
PFE: 8% target was not reached
Lyra published PFE at $27.05 on 2026-03-07 with expected growth of 8%. The thesis was cautious. It pointed to China approval for the obesity drug, steadier healthcare demand in unstable markets, a stock that had begun to steady, and Pfizer's size as reasons for moderate upside rather than a fast move.
Inside the window, PFE rose to a peak of $28.75 on 2026-04-02, a 6.3% gain. It stayed below the $29.21 target and never reached it. By 2026-06-05 it ended at $26.04. The thesis partly played out, but the full target missed.
What happened during the window
On 2026-05-05, Pfizer reported first-quarter revenue of $14.45 billion and adjusted earnings of 75 cents a share. It also kept its full-year outlook at revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3.00 a share.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.